Rakuten Medical, Inc. (Rakuten Medical) today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has notified Rakuten Medical that its lead drug ASP-1929 will be reviewed under the Conditional Early Approval System (CEAS).  Compared to standard review the CEAS speeds up the approval process, bringing potentially life-saving treatments to patients faster. Read more…